Indeed, MET activation has been recognized in RCC and linked to resistance to VEGF(R) inhibition [35,43], and combination treatment with axitinib and crizotinib was highly effective in different models of RCC [43]. The gene discussed is MET; the disease is renal cell carcinoma.